EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Early clinical experience using tecovirimat during the 2022 mpox epidemic in Toronto underscores ongoing clinical equipoise and the need for randomized trials

Shreya S Khera iD, Sharmistha Mishra, Oscar Javier Pico Espinosa, Kevin Gough, Charlie Tan, Sharon Walmsley iD, Alice Zhabokritsky, Malika Sharma, Adrienne K Chan iD, Jerome A Leis, Myo Minn Oo, Darrell H S Tan iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf010 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Shreya S Khera und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, St. Michael's Hospital, 30 Bond St., Toronto, Ontario M5B 1W8, Canada. Hauptthemen laut MEDLINE: Antiviral Agents, Isoindoles, Benzamides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Toronto Emerging and Pandemic Infections Consortium, CIHR, Public Health Agency of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tecovirimat is an antiviral drug that was used compassionately for treating mpox in high-income settings during the 2022 global outbreak. Randomized controlled trials of its efficacy have not yet been completed.

Objectives

To describe medication adherence, tolerability and clinical outcomes of adults receiving open-label tecovirimat for mpox infection.

Methods

We conducted a prospective observational study and a retrospective case series of adults with mpox cared for at three academic hospitals in Toronto, Canada, between May and August 2022. We present a descriptive analysis of those prescribed oral tecovirimat 600 mg twice daily for 14 days for the management of severe manifestations.

Results

Of 69 consenting participants, all were cisgender men, of whom 60 (87%) identified as gay, and 6 (9%) as bisexual. Nearly half (46%) were living with HIV, with a median (IQR) CD4 count of 468 (328–678) cells/mm3, among whom plasma HIV RNA was <20 copies/mL in 29 (91%) participants. One-third (33%) of participants received tecovirimat during the course of their illness. All participants experienced a decline in number of symptoms over time, but three treated participants initially experienced worsening symptoms despite therapy. Self-reported adherence to tecovirimat was excellent and tolerability was good.

Conclusions

Our experience prescribing tecovirimat for mpox suggests it is safe and well tolerated, but the evolution of symptoms in some tecovirimat-treated patients underscores the ongoing uncertainty regarding its efficacy. In the context of considerable community demand for the drug, efforts should be made to connect mpox patients to rigorous randomized controlled trials, given this ongoing clinical equipoise.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsIsoindolesBenzamidesHumansMaleAdultMiddle AgedFemaleProspective StudiesRetrospective StudiesOntarioHIV InfectionsRandomized Controlled Trials as TopicMedication AdherenceTreatment OutcomeMpox, Monkeypox

Substanzen

Antiviral AgentsIsoindolesBenzamides

Autor:innen und Institutionen

  • Division of Infectious Diseases, St. Michael's Hospital, 30 Bond St., Toronto, Ontario M5B 1W8, Canada.
  • MAP Centre for Urban Health Solutions, St. Michael's Hospital, Li Ka Shing Knowledge Institute, 209 Victoria Street, 3rd floor, Toronto, Ontario M5B 1T8, Canada.
  • Department of Medicine, University of Toronto, C. David Naylor Building, 6 Queen's Park Crescent West, Third Floor, Toronto, Ontario M5S 3H2, Canada.
  • Institute of Health Policy, Management, and Evaluation, Dalla Lana School of Public Health, University of Toronto, 155 College Street, 4th Floor, Toronto, Ontario M5T 3M6, Canada.
  • Institute of Medical Science, University of Toronto, 6 Queen's Park Crescent, Suite 119, Toronto, Ontario M5S 3H2, Canada.
  • Institute for Clinical Evaluative Sciences, V1-06 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada.

ORCID-Profile: Shreya S Khera, Sharon Walmsley, Adrienne K Chan, Darrell H S Tan

Förderung

  • University of Toronto Emerging and Pandemic Infections Consortium
  • CIHR
  • Public Health Agency of Canada
  • Canadian Institutes of Health Research

Zitieren

APA

Khera, S. S., Mishra, S., Pico Espinosa, O. J., Gough, K., Tan, C., Walmsley, S., Zhabokritsky, A., Sharma, M., Chan, A. K., Leis, J. A., Oo, M. M., & Tan, D. H. S. (2025). Early clinical experience using tecovirimat during the 2022 mpox epidemic in Toronto underscores ongoing clinical equipoise and the need for randomized trials. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf010

Vancouver

Khera SS, Mishra S, Pico Espinosa OJ, Gough K, Tan C, Walmsley S, et al. Early clinical experience using tecovirimat during the 2022 mpox epidemic in Toronto underscores ongoing clinical equipoise and the need for randomized trials. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf010

BibTeX
@article{Khera2025,
  author = {Khera, Shreya S and Mishra, Sharmistha and Pico Espinosa, Oscar Javier and Gough, Kevin and Tan, Charlie and Walmsley, Sharon and Zhabokritsky, Alice and Sharma, Malika and Chan, Adrienne K and Leis, Jerome A and Oo, Myo Minn and Tan, Darrell H S},
  title = {Early clinical experience using tecovirimat during the 2022 mpox epidemic in Toronto underscores ongoing clinical equipoise and the need for randomized trials},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf010}
}
Kostenlos starten →